A new immunomodulating compound (AS-101) with potential therapeutic application

B. Sredni, R. R. Caspi, A. Klein, Y. Kalechman, Y. Danziger, M. Benya'akov, T. Tamari, F. Shalit, M. Albeck

Research output: Contribution to journalArticlepeer-review

180 Scopus citations

Abstract

There has been interest in the potential of synthetic compounds to modify immune responses by imitation of cytokine action1,2. Direct administration of interleukin 2 (IL-2) in conjunction with adoptive transfer of lymphokine activated killer cells has been used in the treatment of cancer 3,4, but there are toxic effects resulting from the high doses of IL-2 required3,5. We have developed a new synthetic compound, ammonium tri-chloro(dioxoethylene-O,O′-)tellurate (AS-101), which has immunomodulating properties and minimal toxicity. The effects of AS-101 on the activation and function of immunocompetent cells have been assessed. We have found that AS-101 induces proliferation and IL-2 production by human lymphocytes in vitro, and enhances the production of IL-2 and colony-stimulating factor by mouse spleen cells. Splenocytes of BALB/c mice injected with AS-101 increased production of IL-2 and CSF in vitro in the presence of mitogen. Mononuclear cells of normal donors acquired responsiveness to recombinant IL-2 and bound monoclonal antibody to IL-2 receptor after incubation with AS-101. Splenocytes of mice treated in vivo with AS-101 expressed high levels of IL-2 receptor. The stimulation of lymphocytes by AS-101 apparently involves an increase in intracellular free calcium. AS-101 administered systemically to mice mediated antitumour effects which could be attributable to its immunomodulatory properties. In addition, AS-101 could directly enhance the ratio of OKT4 to OKT8-positive cells in cultured mononuclear cells from AIDS (acquired immune deficiency syndrome) patients. These results indicate that AS-101 is potentially useful in the treatment of clinical conditions involving immunosuppression.

Original languageEnglish
Pages (from-to)173-176
Number of pages4
JournalNature
Volume330
Issue number6144
DOIs
StatePublished - 12 Nov 1987

Fingerprint

Dive into the research topics of 'A new immunomodulating compound (AS-101) with potential therapeutic application'. Together they form a unique fingerprint.

Cite this